ClinicalTrials.gg
RecruitingNCT05850234DURGA-1Updated Oct 8, 2026

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

A Phase 1/2 interventional study of AZD0120 in Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca. Recruiting at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
232
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma — 7 open to participants now, 7 under way, 3 of them phase 3. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · Multiple Myeloma.

Planned enrollment
4th of 11
232 · median 40
Started
2023
with 2 others
Phase 1/2
3 of 11
2 open now
Registered
5th of 11
by date
Lead sponsor
5 of 11
AstraZeneca

Among the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 1/2, and was the 5th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F in Multiple Myeloma, or all of them as a file.
02

Study summary

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Read the detailed description

Phase 1b aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, and immunogenicity in subjects with relapsed/refractory multiple myeloma and determine the recommended Phase 2 dose of AZD0120.

Phase II aims to evaluate the efficacy of AZD0120, and to further characterize the safety, pharmacodynamic effects, immunogenicity, and changes in health-related quality of life parameters in subjects with relapsed/refractory multiple myeloma.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma, BCMA, CAR T, CD19, AZD0120
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age at the time of consent.
  • performance status of 0 or 1.
  • Documented diagnosis of MM per IMWG diagnostic criteria.
  • Participant must have received at least 3 , which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.
  • Have documented evidence of progressive disease per IMWG criteria.
  • Participant must have at screening.
  • Participant must have adequate bone marrow and organ function (hematological, hepatic and renal) demonstrated at screening.

Exclusion criteria

Exclusion Criteria :

  • Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy.
  • Participant has a history of a prior non-hematologic , unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply.
  • Participant has significant cardiac, neurological, or psychiatric conditions.
  • Any other significant medical conditions such as:

    • Serious active or uncontrolled infection
    • Active disease or a history of autoimmune disease within 2 years
    • Active plasma cell leukemia at the time of screening
    • Clinical evidence of dementia or altered mental status, or stroke, intracranial haemorrhage, or seizure within 6 months before signing form (ICF).
  • Known active or prior history of central nervous system involvement or exhibits clinical signs of meningeal involvement of MM.

Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    AZD0120

    AZD0120 will be administered by infusion

    Biological: AZD0120

Interventions

  • BiologicalAZD0120

    AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Adverse Events (AEs)

    The incidence and severity of AEs.

    Time frame: Through study completion, a minimum of 2 years.

  2. Phase 1b: Dose-Limiting Toxicities (DLTs)

    The DLT evaluation period is defined as the first 28 days after infusion.

    Time frame: 28 days

  3. Phase 2: Objective Response Rate (ORR)

    Defined as the proportion of participants who achieved partial response (PR) or better by the International Myeloma Working Group (IMWG) response criteria.

    Time frame: Through study completion, a minimum of 2 years.

Secondary outcomes

  1. Phase 1b and 2: Complete response rate (CRR)

    Defined as the proportion of participants who achieved complete response (CR) or better per International Myeloma Working Group (IMWG) criteria.

    Time frame: Through study completion, a minimum of 2 years.

  2. Phase 1b and 2: Time to response (TTR)

    Defined as the time between date of apheresis and the first efficacy evaluation that the participant has met all criteria for partial response (PR) or better.

    Time frame: Through study completion, a minimum of 2 years.

  3. Phase 1b: Objective Response Rate (ORR)

    Defined as the proportion of participants who achieved PR or better by IMWG response criteria.

    Time frame: Through study completion, a minimum of 2 years.

  4. Phase 1b and 2: Minimal Residual Disease (MRD) negative Complete Response (CR) rate

    Defined as the proportion of participants who achieve CR or better response with MRD negativity per IMWG criteria.

    Time frame: Through study completion, a minimum of 2 years.

  5. Phase 1b and 2: Minimal Residual Disease (MRD) negative Complete Response (CR) rate at 12 months

    Defined as the proportion of participants who achieve CR or better response with MRD negativity per IMWG criteria at 12 months.

    Time frame: 12 months

  6. Phase 1b and 2: Duration of response (DOR)

    Defined among responders as the time from the date of initial documentation of an objective response (overall response of PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.

    Time frame: Through study completion, a minimum of 2 years.

  7. Phase 1b and 2: Progression-free survival (PFS)

    Defined as the time from the date of apheresis to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.

    Time frame: Through study completion, a minimum of 2 years.

  8. Phase 1b and 2: Overall survival (OS)

    Defined as the time from the date of apheresis to the date of the subject's death.

    Time frame: Through study completion, a minimum of 2 years.

  9. Phase 2: Adverse Events (AEs)

    Further characterization of the safety of AZD0120 by measuring the incidence and severity of AEs.

    Time frame: Through study completion, a minimum of 2 years.

  10. Ph1b and 2: Pharmacokinetics - AUC

    Area under the concentration time-curve of AZD0120 CAR transgene copies.

    Time frame: Through study completion, a minimum of 2 years.

  11. Ph1b and 2: Pharmacokinetics - Clast

    Last quantifiable AZD0120 CAR transgene copies.

    Time frame: Through study completion, a minimum of 2 years.

  12. Ph1b and 2: Pharmacokinetics - Cmax

    Maximum AZD0120 CAR transgene copies.

    Time frame: Through study completion, a minimum of 2 years.

  13. Ph1b and 2: Pharmacokinetics - Tlast

    Time to last quantifiable AZD0120 CAR transgene copies.

    Time frame: Through study completion, a minimum of 2 years.

  14. Ph1b and 2: Pharmacokinetics - Tmax

    Time to reach maximum AZD0120 CAR transgene copies.

    Time frame: Through study completion, a minimum of 2 years

  15. Ph1b and 2: Humoral Immunogenicity

    Prevalence and incidence of anti-drug antibodies (ADAs) against AZD0120 and the impact on PK, efficacy, and safety, as data allow.

    Time frame: Through study completion, a minimum of 2 years.

  16. Phase 2: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) IL355 Bone Pain and Health-Related Quality of Life Scale Scores

    Change from baseline in patient-reported bone pain and health-related quality of life, as assessed using the European Organization for Research and Treatment of Cancer Item Library 355 (EORTC IL355), including the QL2 scale.

    Time frame: Through study completion, a minimum of 2 years.

  17. Phase 2: Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) IL356 Physical Function and Fatigue Subscale Scores

    Changes from baseline in patient-reported physical function and fatigue, as assessed using the European Organization for Research and Treatment of Cancer Item Library 356 (EORTC IL356).

    Time frame: Through study completion, a minimum of 2 years.

07

Study locations

33 of 36 sites recruiting
  • Research Site
    Birmingham, Alabama 35233, United States
    Recruiting
  • Research Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Research Site
    La Jolla, California 92037, United States
    Recruiting
  • Research Site
    Los Angeles, California 90095, United States
    Recruiting
  • Research Site
    San Francisco, California 94143, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Denver, Colorado 80218, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    Miami, Florida 33136, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Research Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Research Site
    Detroit, Michigan 48202, United States
    Recruiting
  • Research Site
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Omaha, Nebraska 68198, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hackensack, New Jersey 07601, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Buffalo, New York 14203, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Stony Brook, New York 11794, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Durham, North Carolina 27705, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37232, United States
    Recruiting
  • Research Site
    Austin, Texas 78704, United States
    Recruiting
  • Research Site
    Dallas, Texas 75390, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Salt Lake City, Utah 84112, United States
    Recruiting
  • Research Site
    Charlottesville, Virginia 22908, United States
    Recruiting
  • Research Site
    Edmonds, Washington 98026, United States
    Recruiting
  • Research Site
    Seattle, Washington 98109, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 50 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
May 9, 2023
StartActual
Jul 20, 2023
Primary completionEst.
Oct 1, 2027
CompletionEst.
Jan 25, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Withdrawn
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Research Site is now Withdrawn
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05850234
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Jul 20, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Jan 25, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Start the discussion